NY Biotech Gets International IP Coverage For Growing Portfolio Of Psychedelic-Derived Novel Drugs

New York-based therapeutics biotech platform Terran Biosciences published a new World International Patent Organization (WIPO) application under the Patent Cooperation Treaty (PCT) to protect its novel, non-hallucinogenic psychoplastogens inspired in DMT and ibogaine with improved drug profiles.

See also: International IP Claims On Novel Psychedelic Fungi Biomass Manufacturing Gets Prelim Acceptance

While first-generation DMT has shown positive results in the treatment of depression and ibogaine for that of Substance Use Disorders (SUDs,) Terran’s designed next-gen compounds have demonstrated more favorable pharmacokinetic (PK) profiles in the preclinical stage in terms of receptor-binding (in vitro studies) and not inducing human hallucinations-related behaviors (animal model studies. 

The innovative chemistry and design of the DMT-based compounds are detailed in the "N-Substituted Indolines" application, and that of the ibogaine-based entities can be found in the "Azepino-indoles for the treatment of neurological and psychiatric disorders” application.

Terran CEO Dr. Sam Clark says the company believes that a medicine holding the benefits of psychedelics without inducing hallucinations “could provide the most favorable use profile to enable widespread use.” 

While several other companies are working on the design of non-hallucinogenic, psychedelic-inspired compounds, as seen most recently in the filing of another international patent covering a new class of non-tryptamine entities, Terran has published other PCT applications for novel prodrugs based on MDMA and 5-MeO-DMT earlier this year.

Photo: Benzinga edit with photo by Olia Danilevich on Pexels.